journal article·2021-06-23

Formulation of Nanovaccines toward an Extended Immunity against Nicotine

Yun Hu, Zongmin Zhao, Marion Ehrich, Chenming Zhang

ACS Applied Materials & Interfaces· Volume 13· Issue 24
Publisher page

Abstract

Nicotine vaccines have been investigated to assist with smoking cessation. Because smoking cessation is a long process, past nicotine vaccines required multiple injections to achieve long-term efficacy. It would be of great significance if extended efficacy can be achieved with fewer injections. Here, we report the assembly of lipid-polylactic acid (PLA) and lipid-poly(lactic- co -glycolic acid) (PLGA) hybrid nanoparticle (NP) based nicotine vaccines. Mice immunized with the lipid-PLGA vaccine produced higher titers of nicotine-specific antibodies than the lipid-PLA vaccine in short-term. However, the lipid-PLA vaccine was found to induce long-lasting antibodies. Three months after the immunization, only mice that received first two injections of the lipid-PLGA vaccine and a third injection of the lipid-PLA vaccine achieved a significantly lower brain nicotine concentration of 65.13 ± 20.59 ng/mg than 115.88 ± 37.62 ng/mg from the negative controls. The results indicate that not only the stability of the vaccines but also the combination of the vaccines impacted the long-term efficacy of the immunization. Lastly, both the body weight and the histopathology study suggest that the vaccines were safe to mice. These findings suggest that long-term immunity against nicotine can be realized by a rational administration of nanovaccines of different levels of stability.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Plant Ecology and Soil Science

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Systems Engineering, Virginia Tech, Blacksburg, Virginia 24061, United States

Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, Virginia 24061, United States

Funding

National Institute on Drug Abuse

References (61)

Show source-provided references
1. 10.15585/mmwr.mm6738a710.15585/mmwr.mm6738a7 ↗
2. 10.1016/B978-0-12-420118-7.00014-710.1016/B978-0-12-420118-7.00014-7 ↗
3. 10.1016/j.tips.2010.12.00810.1016/j.tips.2010.12.008 ↗
4. 10.2165/11599900-000000000-0000010.2165/11599900-000000000-00000 ↗
5. 10.1002/14651858.CD007072.pub210.1002/14651858.CD007072.pub2 ↗
6. 10.1093/ntr/ntt00310.1093/ntr/ntt003 ↗
7. 10.1038/clpt.2011.28110.1038/clpt.2011.281 ↗
8. 10.1016/j.amepre.2010.11.01610.1016/j.amepre.2010.11.016 ↗
9. 10.1021/jm501625j10.1021/jm501625j ↗
10. 10.1016/j.intimp.2013.03.02110.1016/j.intimp.2013.03.021 ↗
11. 10.1016/S0024-3205(02)01523-010.1016/S0024-3205(02)01523-0 ↗
12. 10.1016/j.nano.2016.07.01510.1016/j.nano.2016.07.015 ↗
13. 10.1016/j.biomaterials.2017.11.02110.1016/j.biomaterials.2017.11.021 ↗
14. 10.1016/j.biomaterials.2016.08.02810.1016/j.biomaterials.2016.08.028 ↗
15. 10.1016/j.biomaterials.2017.01.03810.1016/j.biomaterials.2017.01.038 ↗
16. 10.1016/j.biomaterials.2018.08.01510.1016/j.biomaterials.2018.08.015 ↗
17. 10.1166/jbn.2015.215610.1166/jbn.2015.2156 ↗
18. 10.4155/tde.14.9110.4155/tde.14.91 ↗
19. 10.1016/j.addr.2016.06.01810.1016/j.addr.2016.06.018 ↗
20. 10.1021/acsnano.5b0021410.1021/acsnano.5b00214 ↗
21. 10.1021/acsami.7b0602410.1021/acsami.7b06024 ↗
22. 10.1021/acsnano.6b0208610.1021/acsnano.6b02086 ↗
23. 10.1021/acsnano.6b0734310.1021/acsnano.6b07343 ↗
24. 10.1021/acsami.0c1234110.1021/acsami.0c12341 ↗
25. 10.1038/nnano.2007.22310.1038/nnano.2007.223 ↗
26. 10.2147/IJN.S3611110.2147/IJN.S36111 ↗
27. 10.4049/jimmunol.100120510.4049/jimmunol.1001205 ↗
28. 10.1016/S0952-7915(96)80124-510.1016/S0952-7915(96)80124-5 ↗
29. 10.1007/s40264-015-0350-410.1007/s40264-015-0350-4 ↗
30. 10.3389/fimmu.2018.0222410.3389/fimmu.2018.02224 ↗
31. 10.1007/s12033-007-0006-410.1007/s12033-007-0006-4 ↗
32. 10.1016/j.biomaterials.2007.07.02910.1016/j.biomaterials.2007.07.029 ↗
33. 10.1016/S0092-8674(01)00449-410.1016/S0092-8674(01)00449-4 ↗
34. 10.1038/3258810.1038/32588 ↗
35. 10.1038/7973410.1038/79734 ↗
36. 10.1016/j.copbio.2015.03.01410.1016/j.copbio.2015.03.014 ↗
37. 10.1021/nn302639r10.1021/nn302639r ↗
38. 10.1016/j.vaccine.2012.11.03610.1016/j.vaccine.2012.11.036 ↗
39. 10.3389/fimmu.2013.0011410.3389/fimmu.2013.00114 ↗
40. 10.1016/j.nano.2019.10202310.1016/j.nano.2019.102023 ↗
41. 10.1111/add.1257310.1111/add.12573 ↗
42. 10.1016/j.tips.2015.07.00210.1016/j.tips.2015.07.002 ↗
43. 10.1007/s00726-010-0628-x10.1007/s00726-010-0628-x ↗
44. 10.3389/fimmu.2014.0052010.3389/fimmu.2014.00520 ↗
45. 10.1016/j.smim.2004.02.00810.1016/j.smim.2004.02.008 ↗
46. 10.1016/j.immuni.2010.10.00810.1016/j.immuni.2010.10.008 ↗
47. 10.4161/hv.2663510.4161/hv.26635 ↗
48. 10.1016/j.vaccine.2005.06.02410.1016/j.vaccine.2005.06.024 ↗
49. 10.1371/journal.pone.014898410.1371/journal.pone.0148984 ↗
50. 10.1126/science.107607110.1126/science.1076071 ↗
51. 10.3410/B2-8710.3410/B2-87 ↗
52. 10.1172/JCI8108310.1172/JCI81083 ↗
53. 10.1172/JCI7795610.1172/JCI77956 ↗
54. 10.2147/IJN.S13682010.2147/IJN.S136820 ↗
55. 10.14202/vetworld.2018.819-82310.14202/vetworld.2018.819-823 ↗
56. 10.1586/erv.13.1310.1586/erv.13.13 ↗
57. 10.1016/j.biomaterials.2017.05.03110.1016/j.biomaterials.2017.05.031 ↗
58. 10.1371/journal.pone.007655710.1371/journal.pone.0076557 ↗
59. 10.1016/j.intimp.2008.07.00110.1016/j.intimp.2008.07.001 ↗
60. 10.1124/jpet.107.13511110.1124/jpet.107.135111 ↗
61. 10.1038/3510058510.1038/35100585 ↗